It is widely accepted that anti-β2GPI antibodies play a pathogenic role in APS and have been shown to induce activation of ECs, in vitro and in vivo, which may contribute to hypercoagulability in APS patients [12, 25–26]. The gene discussed is APOH; the disease is thrombophilia.